[go: up one dir, main page]

AR080730A1 - Uso del fitocanabinoide canabidivarina (cbdv) en el tratamiento de la epilepsia - Google Patents

Uso del fitocanabinoide canabidivarina (cbdv) en el tratamiento de la epilepsia

Info

Publication number
AR080730A1
AR080730A1 ARP110101014A AR080730A1 AR 080730 A1 AR080730 A1 AR 080730A1 AR P110101014 A ARP110101014 A AR P110101014A AR 080730 A1 AR080730 A1 AR 080730A1
Authority
AR
Argentina
Prior art keywords
cbdv
canabidivarine
epilepsy
treatment
phytochanabinoid
Prior art date
Application number
Other languages
English (en)
Inventor
Ben Whalley
Gary Stephens
Takashi Futamura
Clare Williams
Original Assignee
Gw Pharma Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1005364.3A external-priority patent/GB2479153B/en
Priority claimed from GB1100042.9A external-priority patent/GB2487183B/en
Application filed by Gw Pharma Ltd, Otsuka Pharma Co Ltd filed Critical Gw Pharma Ltd
Publication of AR080730A1 publication Critical patent/AR080730A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso del fitocanabinoide canabidivarina (CBDV) y de combinaciones del fitocanabinoide CBDV con tetrahidrocanabivarina (THCV) y canabidiol (CBD) en el tratamiento de la epilepsia. Uso del fitocanabinoide CBDV en combinacion con drogas antiepilépticas convencionales (SAED). Preferiblemente, la SAED es una seleccionada del siguiente grupo: la etosuximida, el valproato y el fenobarbital.
ARP110101014 2010-03-30 2011-03-28 Uso del fitocanabinoide canabidivarina (cbdv) en el tratamiento de la epilepsia AR080730A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1005364.3A GB2479153B (en) 2010-03-30 2010-03-30 The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB1100042.9A GB2487183B (en) 2011-01-04 2011-01-04 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy

Publications (1)

Publication Number Publication Date
AR080730A1 true AR080730A1 (es) 2012-05-02

Family

ID=43983229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101014 AR080730A1 (es) 2010-03-30 2011-03-28 Uso del fitocanabinoide canabidivarina (cbdv) en el tratamiento de la epilepsia

Country Status (19)

Country Link
US (3) US9125859B2 (es)
EP (2) EP3763361B1 (es)
JP (1) JP5918748B2 (es)
KR (1) KR101849703B1 (es)
CN (1) CN103025325B (es)
AR (1) AR080730A1 (es)
AU (3) AU2011234225B2 (es)
BR (1) BR112012024480A8 (es)
CA (1) CA2794620C (es)
EA (1) EA036044B1 (es)
IL (1) IL222132B (es)
MX (1) MX2012011033A (es)
MY (1) MY162129A (es)
NZ (1) NZ602925A (es)
PH (1) PH12012501902A1 (es)
SG (2) SG184236A1 (es)
TW (1) TWI583374B (es)
WO (1) WO2011121351A1 (es)
ZA (1) ZA201208141B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054057A2 (en) * 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2487183B (en) * 2011-01-04 2018-10-03 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
CA3013907C (en) * 2013-10-29 2020-09-08 Biotech Institute, Llc Production and use of specialty cannabis with bd/bt genotype and a limonene-dominant terpene profile
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
EP3193862B1 (en) 2014-09-16 2023-10-18 Igc Pharma Ip, Llc Topical cannabinoid composition for treating arthritic pain
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
WO2016118391A1 (en) * 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
EP3250200A4 (en) 2015-01-31 2018-09-19 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
AU2016225026A1 (en) 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
WO2016176279A1 (en) * 2015-04-28 2016-11-03 The Regents Of The University Of California Uses of cannabidiol for treatment of infantile spasms
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
US10806707B2 (en) 2015-11-24 2020-10-20 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
US10053407B2 (en) 2016-06-01 2018-08-21 S&B Pharma, Inc. Crystalline cannabidivarin
US11351152B2 (en) 2016-06-15 2022-06-07 India Globalization Capital, Inc. Method and composition for treating seizure disorders
CA3010636A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
CA3031810A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
WO2018044953A1 (en) 2016-08-29 2018-03-08 Ebbu, LLC Water soluble compositions comprising purified cannabinoids
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
EP3589129A4 (en) * 2017-03-01 2020-11-25 Canopy Growth Corporation TARGETEDLY SELECTED COMPOSITIONS CONTAINING PURIFIED CANNABINOIDS AND / OR PURIFIED TERPENES
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
CN109106699A (zh) * 2017-06-23 2019-01-01 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
CN109498606A (zh) 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CA3085010A1 (en) * 2017-12-08 2019-06-13 Biotech Institute LLC Propyl cannabinoid hemp plants, methods of producing and methods of using them
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2020123383A1 (en) * 2018-12-10 2020-06-18 Natural Extraction Systems, LLC Compositions with novel cannabinoid and terpene profiles
AU2020236953A1 (en) * 2019-03-08 2021-09-30 The Regents Of The University Of California Use of 8,9-dihydrocannabidiol compounds
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB201916977D0 (en) * 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
EP4069215A4 (en) 2019-12-06 2024-01-17 Jlabs Beauty LLC TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF PREPARING AND USING THE SAME
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
KR102371269B1 (ko) 2020-03-11 2022-03-07 연세대학교 산학협력단 VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법
CA3177186A1 (en) * 2020-03-31 2021-10-07 Phytotherapeutix Ltd Terpenophenolic compounds and their use
CA3179442A1 (en) 2020-05-22 2021-11-25 Brian Warrington Compositions for treating acne and dermatological conditions
WO2022026613A2 (en) 2020-07-28 2022-02-03 Impello Biosciences, Inc. Methods and compositions for altering secondary metabolites in plants
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
GB202014250D0 (en) * 2020-09-10 2020-10-28 Gw Res Ltd Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
WO2022122904A1 (en) 2020-12-09 2022-06-16 Chanelle Mccoy Cbd Limited A delayed-release capsule of cannabidiol
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
GB2606334A (en) 2021-02-12 2022-11-09 Gw Res Ltd Use of cannabidivarin in the treatment of seizures associated with canine epilepsy
CN115583933B (zh) * 2022-10-31 2024-02-06 暨明医药科技（苏州）有限公司 一种高纯度四氢大麻素同系物的制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
GB0103638D0 (en) * 2001-02-14 2001-03-28 Gw Pharmaceuticals Ltd Pharmaceutical formulations
AU2002231970B2 (en) * 2001-02-14 2007-08-16 Jazz Pharmaceuticals Research Uk Limited Mucoadhesive pharmaceutical formulations
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) * 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
PL226646B1 (pl) 2002-08-14 2017-08-31 Gw Pharma Ltd Botaniczna substancja lekowa
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
DK1542657T3 (da) * 2002-08-14 2012-03-05 Gw Pharma Ltd Flydende cannabinoidformuleringer til administration via en slimhinde
WO2006054057A2 (en) * 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2007142957A2 (en) 2006-05-30 2007-12-13 Air Systems Gear drive damper
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
WO2008094181A2 (en) 2007-02-01 2008-08-07 The Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
ES2727648T3 (es) 2008-03-26 2019-10-17 Stichting Sanammad Composiciones de goma de mascar que comprenden cannabinoides
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
US9750747B2 (en) 2011-08-26 2017-09-05 Bail-Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
NZ726746A (en) 2014-05-29 2020-08-28 Fresh Cut Dev Llc Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
US20150320698A1 (en) 2015-11-12
ZA201208141B (en) 2013-06-26
TW201138759A (en) 2011-11-16
SG10201502480XA (en) 2015-05-28
EA036044B1 (ru) 2020-09-17
WO2011121351A1 (en) 2011-10-06
JP5918748B2 (ja) 2016-05-18
PH12012501902A1 (en) 2012-12-01
TWI583374B (zh) 2017-05-21
MX2012011033A (es) 2013-02-26
CN103025325B (zh) 2016-03-16
BR112012024480A8 (pt) 2018-04-03
US12023305B2 (en) 2024-07-02
US9125859B2 (en) 2015-09-08
AU2016244223A1 (en) 2016-11-03
AU2018217303A1 (en) 2018-09-06
AU2011234225A1 (en) 2012-11-08
JP2013523708A (ja) 2013-06-17
EP3763361A1 (en) 2021-01-13
EP3763361B1 (en) 2024-06-26
NZ602925A (en) 2014-11-28
US20210100755A1 (en) 2021-04-08
CA2794620A1 (en) 2011-10-06
CA2794620C (en) 2018-03-13
US20120004251A1 (en) 2012-01-05
SG184236A1 (en) 2012-10-30
CN103025325A (zh) 2013-04-03
KR20130065646A (ko) 2013-06-19
US10799467B2 (en) 2020-10-13
EA201290975A1 (ru) 2013-04-30
MY162129A (en) 2017-05-31
IL222132B (en) 2018-04-30
KR101849703B1 (ko) 2018-04-17
AU2011234225B2 (en) 2016-11-03
EP2552430A1 (en) 2013-02-06
BR112012024480A2 (pt) 2016-05-31
EA201290975A8 (ru) 2017-02-28

Similar Documents

Publication Publication Date Title
AR080730A1 (es) Uso del fitocanabinoide canabidivarina (cbdv) en el tratamiento de la epilepsia
ES2877502T8 (es) Uso del fitocannabinoide cannabidiol (CBD) en combinación con un fármaco antiepiléptico estándar (SAED) en el tratamiento de la epilepsia
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
MX2019008337A (es) Uso de cannabinoides para el tratamiento de epilepsia.
MX2020006951A (es) Uso de cannabinoides en el tratamiento de epilepsia.
UA109271C2 (uk) Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CU24336B1 (es) Compuestos de imidazopirrolidinona
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
DOP2016000176A (es) Insulina de acción prolongada y uso de la misma
CL2014002975A1 (es) Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
MX2017002323A (es) Variantes de desintegrina y usos farmaceuticos de las mismas.
BR112015002531A2 (pt) composição, método de tratamento de hipersensibilidade e uso de carbonato de cálcio.
CL2009001018A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona.
WO2013138338A3 (en) Methods for treating tissue damage associated with ischemia with apoliporotein d
BR112015002551A2 (pt) composição, método de tratamento para hipersensibilidade e uso do carbonato de cálcio particulado.
AR089060A1 (es) Composiciones para el cuidado bucal
CL2012002925A1 (es) Concentrado en suspensión que comprende sustancia activa agroquimica, aceite, emulsionante y al menos un triglicéridos; uso del concentrado en suspensión para mejorar la tasa de deposición de sustancias activas agroquímicas sobre las plantas.
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
PH12017500084A1 (en) Vitamin b2 and its use
AR101442A1 (es) Método para la expansión de células madre de adultos de sangre

Legal Events

Date Code Title Description
FB Suspension of granting procedure